MC

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

MC

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

MC

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

MC

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

MC

491.35

-1.14%↓

SANES

8.313

+0.48%↑

SAF

280.3

+0.14%↑

BBVA

15.935

+0.85%↑

BNP

77.86

+1.37%↑

Search

AB Science SA

Slēgts

1.184 0.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.164

Max

1.214

Galvenie mērījumi

By Trading Economics

Ienākumi

-3.4M

Pārdošana

512K

Peļņas marža

-656.641

Darbinieki

28

EBITDA

-1.9M

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

87M

Iepriekšējā atvēršanas cena

0.33

Iepriekšējā slēgšanas cena

1.184

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

AB Science SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. sept. 23:59 UTC

Iegādes, apvienošanās, pārņemšana

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025. g. 8. sept. 22:02 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Tron Shares Rise After New Investment From Bravemorning

2025. g. 8. sept. 16:14 UTC

Galvenie tirgus virzītāji

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025. g. 8. sept. 16:13 UTC

Galvenie tirgus virzītāji

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025. g. 8. sept. 22:56 UTC

Tirgus saruna

Worst May Be Over for New Zealand Retailers -- Market Talk

2025. g. 8. sept. 22:23 UTC

Tirgus saruna

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025. g. 8. sept. 21:51 UTC

Tirgus saruna

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025. g. 8. sept. 21:47 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4B AI Deal With Nebius

2025. g. 8. sept. 21:33 UTC

Iegādes, apvienošanās, pārņemšana

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025. g. 8. sept. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025. g. 8. sept. 21:19 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025. g. 8. sept. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025. g. 8. sept. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 19:33 UTC

Tirgus saruna

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025. g. 8. sept. 19:22 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025. g. 8. sept. 19:02 UTC

Tirgus saruna

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025. g. 8. sept. 17:29 UTC

Tirgus saruna

Mexican Inflation Seen Little Changed in August -- Market Talk

2025. g. 8. sept. 16:59 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025. g. 8. sept. 16:36 UTC

Tirgus saruna

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025. g. 8. sept. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 16:16 UTC

Peļņas

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025. g. 8. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 8. sept. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

AB Science SA Prognoze

Tehniskais rādītājs

By Trading Central

1.426 / 1.448Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
help-icon Live chat